Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orchid PharmaLUX:ORCHP 56 Cash Ratio is 0.30 as of Mar. 2026, which is 100% above its 10-year median of 0.15. GuruFocus rates LUX:ORCHP with a GF Score™ of 56/100 and a GF Value™ of $4.68. The stock has 10 warning signs investors should review. Among 971 Drug Manufacturers companies, Orchid Pharma ranks worse than 65.91% on this metric.
Orchid Pharma has a Cash Ratio of 0.30. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Orchid Pharma's Cash Ratio or its related term are showing as below:
LUX:ORCHP'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.15 Max: 0.51
Current: 0.3
During the past 13 years, Orchid Pharma's highest Cash Ratio was 0.51. The lowest was 0.02. And the median was 0.15.
LUX:ORCHP's Cash Ratio is ranked worse than 65.91% of 971
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs LUX:ORCHP: 0.30
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Orchid Pharma Cash Ratio Related Terms
Orchid Pharma Cash Ratio Historical Data
* Premium members only.
The historical data trend for Orchid Pharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchid Pharma (LUX:ORCHP) has a Cash Ratio of 0.30 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Orchid Pharma and its competitors. This is 100% above median its historical median of 0.15. Over the past decade, Orchid Pharma's Cash Ratio has ranged from 0.02 to 0.51. According to the industry distribution chart, Orchid Pharma ranks #640 out of 971 companies in the Drug Manufacturers industry, placing it in the top 65.9%.
Is Orchid Pharma's Cash Ratio too high?
Orchid Pharma's current Cash Ratio of 0.30 is 100% above median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.51. The Drug Manufacturers industry median Cash Ratio is 0.60. Orchid Pharma's value of 0.30 is 50% below this industry median. Based on the distribution chart, Orchid Pharma ranks #640 out of 971 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orchid Pharma has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orchid Pharma ranks #640 out of 971 companies for Cash Ratio. This places Orchid Pharma in the lower half of its industry. The industry median Cash Ratio is 0.60. Orchid Pharma's value of 0.30 is 50% below this benchmark. Historically, Orchid Pharma's own Cash Ratio has ranged from 0.02 to 0.51 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.60, Orchid Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.60, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchid Pharma's current Cash Ratio of 0.30 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Orchid Pharma and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchid Pharma's current Cash Ratio is 0.30, which is 100% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current Cash Ratio of 0.30. The stock's GF Value™ is $4.68, compared to a current price of $5.45 — trading 16.5% above its estimated fair value. The current Cash Ratio is 0.30, which is 100% above median its 10-year median of 0.15 and 50% below the Drug Manufacturers industry median of 0.60. Orchid Pharma's overall GF Score™ is 56/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current Cash Ratio is 0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?
Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued.
The current stock price of $5.45 is trading 16.5% above its estimated GF Value™ of $4.68.
Key valuation signals for LUX:ORCHP:
Cash Ratio: 0.30 (100% above median its 10-year median of 0.15)
GF Value™: $4.68 vs. price of $5.45 (16.5% above fair value)
Industry Position: 50% below the Drug Manufacturers median (#640 of 971)
No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
56GF Score
Get the complete analysis for LUX:ORCHP
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ORCHP has been successfully added to your 
